title: [Recommendations on the use of rituximab for ANCA-associated vasculitis].
abstract: Rituximab (Rtx) has been approved in Germany since April 2013 for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This therapy can be used in severe manifestations of these diseases and in relapses. It is administered as infusions of 375 mg rituximab per m(2) every 4 weeks after high dose intravenous prednisolone for 3 days and continued parallel to concomitant oral prednisolone therapy. Recommendations for the indications and use for antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) are described in addition to previous publications on recommendations for rheumatoid arthritis.
authors.affiliation: Rheumapraxis Bad Bramstedt, Sommerland 55, 24576, Bad Bramstedt, Deutschland. amgause@rheuma-bb.de.
authors.forename: A M
authors.initials: AM
authors.lastname: Gause
authors.affiliation: Klinik I für Innere Medizin, Uniklinik Köln, Köln, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Rubbert-Roth
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000175:diagnosis* / Q000188:drug therapy*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D000069283:Rituximab / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007155:Immunologic Factors; D000069283:Rituximab
keywords: Cyclophosphamide; Granulomatosis with polyangiitis; Microscopic polyangiitis; Remission induction; Side effects